Body Mass Index Did Not Affect Efficacy and Safety of Etrasimod: A Post Hoc Analysis of the ELEVATE Ulcerative Colitis Clinical Program.

ABSTRACT:

Introduction

High body mass index (BMI) may reduce ulcerative colitis (UC) treatment efficacy. Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate 1,4,5 receptor modulator for the treatment of moderately to severely active UC. This post hoc analysis assessed treatment outcomes according to BMI in ELEVATE UC 52 and ELEVATE UC 12.

Methods

Patients receiving etrasimod 2 mg QD or placebo were stratified by BMI: <25, 25-30, and >30 kg/m 2 . Efficacy and safety were assessed at weeks 12 (pooled data) and 52 (ELEVATE UC 52 only) in addition to biomarkers assessments from week 0-12.

Results

For BMI <25 (N = 443) and 25-30 kg/m 2 (N = 217) subgroups, more patients receiving etrasimod vs placebo achieved clinical remission at weeks 12 (BMI <25 kg/m 2 : 27.9

SUBMITTER: Yarur AJ 

PROVIDER: S-EPMC12570604 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature